A Study to Assess the Pharmacokinetics, Safety and Tolerability of CT327 in Healthy Male Volunteers

NCT01243502 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Safety

Interventions

DRUG: 0.01% CT327 (or placebo)
DRUG: 0.001% CT327 (or placebo)

Sponsor

Creabilis SA

Collaborators

[object Object]